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Abstract
Background:  High expression of P-glycoprotein is one of the well-known mechanisms of
chemoresistance in chondrosarcomas. However, the role of antiapoptotic proteins, a common
mechanism responsible for chemoresistance in other tumors, has not been well studied in
chondrosarcomas. We examined the importance of P-glycoprotein and antiapoptotic proteins in
the chemoresistance to doxorubicin of two Grade II chondrosarcoma cell lines, JJ012 and SW1353.
Results:  We confirmed that both chondrosarcoma cell types expressed P-glycoprotein and
antiapoptotic proteins (Bcl-2, Bcl-xL and XIAP). siRNA knockdown as well as pharmacologic
inhibitors of cell survival proteins (Bcl-2, Bcl-xL and XIAP) enhanced apoptosis of chemoresistant
chondrosarcoma cells by up to 5.5 fold at 0.1 μmol and 5.5 fold at 1 μmol doxorubicin. These
chemosensitizing effects were comparable to those of P-glycoprotein inhibition by siRNA or
pharmacologic inhibitor.
Conclusion:  These findings suggest that antiapoptotic proteins play a significant role in the
chemoresistance of chondrosarcoma cells independent of P-glycoprotein. Based on the results, a
new siRNA-based therapeutic strategy targeting antiapoptotic genes can be designed to overcome
the chemoresistance of chondrosarcomas which is often conferred by P-glycoprotein.
Background
Chondrosarcoma is the second most common sarcoma
arising in bones and the main treatment is surgical resec-
tion with a wide margin. However, there is no effective
therapeutic option for metastatic chondrosarcoma
patients since chondrosarcoma is resistant to both chem-
otherapy and radiation therapy [1,2]. Therefore, it is nec-
essary to explore new therapeutic approaches for
metastatic and surgically unresectable chondrosarcoma
cases. P-glycoprotein, a product of multidrug resistant
gene 1, and antiapoptotic protein overexpression are two
common mechanisms of chemoresistance in tumor cells.
It has already been reported that chondrosarcoma cells
highly express P-glycoprotein and antiapoptotic proteins
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(Bcl-2, Bcl-xL, XIAP) [3-6]. The role of P-glycoprotein in
drug efflux has been identified as one of the mechanisms
for chemoresistance in human chondrosarcoma cells
[3,7], while the function of antiapoptotic genes in chem-
oresistance has not been elucidated.
P-glycoprotein is a transmembrane ATP-dependent pump
that transports drugs out of cells as protection against tox-
ins. Tumor cells exposed to a single cytotoxic drug are
resistant to structurally and functionally unrelated drugs,
and P-glycoprotein is largely responsible for this multid-
rug resistance (MDR) [8,9]. MDR resulting from the over-
expression of P-glycoprotein has been reported in
different types of soft tissue sarcomas (eg, malignant
fibrous histiocytoma, liposarcoma, leiomyosarcoma,
Ewing's sarcoma) and hematologic malignancies (eg,
multiple myeloma, acute myeloid or lymphoblastic
leukemia) [10,11]. In addition to drug transportation, P-
glycoprotein overexpressing cells exhibit abrogation of
mitochondrial cytochrome c release and caspase-3 activa-
tion, which may be dependent on Bcl-xL overexpression
[12]. Bcl-xL, one of the well-known antiapoptotic Bcl-2
family members, controls apoptosis by blocking the
release of cytochrome c from the mitochondria. Further-
more, the activation of caspases, the effector molecules of
apoptosis, is dependent on this cytochrome c release. It
has been reported that the inhibition of apoptosis can
lead to tumorigenesis and resistance to chemotherapy and
radiotherapy in carcinomas [13,14]. Although the role of
antiapoptotic proteins in the chemoresistance of chond-
rosarcoma is not well understood, the overexpression of
antiapoptotic proteins (Bcl-2, Bcl-xL, XIAP) is one of the
mechanisms of radiation resistance in chondrosarcoma
cells [4]. Since chemotherapeutic agents and radiation
therapy both induce apoptotic cell death [15,16], antiap-
optotic proteins may contribute to chemoresistance, as
well. Several studies have suggested that antiapoptotic
proteins have a major role in chemoresistance [17,18].
Chondrosarcoma cells with MDR properties conferred by
membrane-bound P-glycoprotein still have a significant
amount of cytoplasmic levels of doxorubicin remaining
after doxorubicin treatment and washout, which further
supports the involvement of antiapoptotic proteins in
chemoresistance [7].
Based on these findings, we hypothesize (1) antiapoptotic
proteins mediate chemoresistance in chondrosarcoma
cells and (2) the knockdown of these proteins, as well as
P-glycoprotein, would enhance chemosensitivity to the
doxorubicin remaining in the cells.
Results
Chondrosarcoma cells are resistant to chemotherapy
In order to verify the chemoresistance of chondrosarcoma
cells, we treated well-known human grade II chondrosar-
coma cells, SW1353 and JJ012 [19-21], with doxorubicin
in vitro. Doxorubicin treatment did not increase apoptosis
in chondrosarcoma cells while human embryonic kidney
(HEK) cells were undergoing robust apoptosis (Figure
1A). Normal chondrocyte cells also exhibited chemore-
sistance, suggesting that chondrocytes, in general, are
chemoresistant. To confirm P-glycoprotein and antiapop-
totic protein expression as a possible mechanism of chem-
oresistance in chondrosarcoma, we measured P-
glycoprotein, Bcl-2, Bcl-xL and XIAP expression by immu-
noblotting (Figure 1B). Normal chondrocytes and chond-
rosarcoma cells express all these proteins, suggesting that
both P-glycoprotein and antiapoptotic proteins may con-
tribute to doxorubicin resistance.
To investigate the effect of doxorubicin, we measured pro-
tein expression after doxorubicin treatment (Figure 1C).
Doxorubicin resistance and expression of antiapoptotic pro- tein and P-glycoprotein in chondrosarcoma cells Figure 1
Doxorubicin resistance and expression of antiapop-
totic protein and P-glycoprotein in chondrosarcoma 
cells. (A) Detection of apoptosis by flow cytometry after 
doxorubicin treatment. Two normal articular chondrocytes 
(NC1 and NC2) and two chondrosarcoma cells (SW: 
SW1353 and JJ: JJ012) showed chemoresistance when com-
pared to human embryonic kidney cells (HEK). (B) Immunob-
lotting anti-apoptotic proteins (Bcl-2, Bcl-xL, and XIAP) and 
P-glycoprotein. Bcl-2, Bcl-xL, XIAP and P-glycoprotein 
expressions were verified in two normal chondrocytes (NC1 
and NC2) and two chondrosarcoma cells (SW: SW1353, JJ: 
JJ012). (C) Immunoblotting anti-apoptotic proteins (Bcl-2, 
Bcl-xL, and XIAP) and P-glycoprotein in two chondrosar-
coma cells after doxorubicin treatment. Bcl-2, Bcl-xL, XIAP 
and P-glycoprotein expressions were not changed signifi-
cantly after doxorubicin treatment.Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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Doxorubicin treatment did not significantly change
expression levels of P-glycoprotein and antiapoptotic pro-
teins in both chondrosarcoma cell types.
P-glycoprotein is expressed on the cell surface and expels 
doxorubicin from the cells
Membrane-bound P-glycoprotein expression and doxoru-
bicin uptake were measured by flowcytometry. P-glyco-
protein was present on the cell surface of both
chondrosarcoma cell types (Figure 2A). Doxorubicin has
inherent autofluorescent (excitation wavelength: 480 nm,
emission wavelength: 580 nm) and intracellular doxoru-
bicin uptake was measured. Our results show that as dox-
orubicin dose increased, the number of fluorescent cells
increased (Figure 2B). To examine the functional activity
of P-glycoprotein, we measured doxorubicin levels in
chondrosarcoma cells after doxorubicin washout. Doxo-
rubicin levels decreased in cells in a time dependant man-
ner (Figure 2C). However, a substantial amount of
doxorubicin still remained 24 hours after doxorubicin
washout (Figure 2C). These data suggest that P-glycopro-
tein may not be the only responsible mechanism for
chemoresistance by chondrosarcoma cells.
Pharmacologic inhibitors of antiapoptotic protein and P-
glycoprotein enhance doxorubicin sensitivity
We showed that P-glycoprotein does not completely elim-
inate doxorubicin from chondrosarcoma cells. We
hypothesize that antiapoptotic proteins have a critical role
in chemoresistance since a significant amount of doxoru-
bicin remains within chondrosarcoma cells. To test our
hypothesis, we treated cells with inhibitors of antiapop-
totic proteins and P-glycoprotein in the presence or
absence of doxorubicin. First, we performed a dose-
response experiment using 3 different doses of pharmaco-
logic inhibitors based on previously published reports in
order to find an optimal concentration that is least cyto-
toxic [22-24]. There were no significant changes in the rate
of apoptosis with 10 μM of Bcl-2 inhibitor (2.36 ±
0.67%), 10 μM of C-4 (3.19 ± 0.91%) or 10 μM of embe-
lin (3.53 ± 1.75%) when compared with the DMSO
treated control group (1.53 ± 0.74%). Based on these
data, chondrosarcoma cells were treated with 10 μM of
Bcl-2 inhibitor, 10 μM of C-4 (P-glycoprotein inhibitor)
or 10 μM of embelin (XIAP inhibitor) and two different
concentrations of doxorubicin (0.1 μM and 1 μM). Apop-
tosis rates were measured to investigate whether or not
inhibition of antiapoptotic proteins or P-glycoprotein
would enhance doxorubicin sensitivity in chondrosar-
coma cells. While the DMSO treated chondrosarcoma
cells exhibited chemoresistance (SW1353; 2.42 ± 0.96%
at 0.1 μM, 4.24 ± 2.53% at 1 μM. JJ012; 2.5 ± 0.76% at 0.1
μM, 4.26 ± 0.9% at 1 μM), inhibition of Bcl-2, XIAP and
P-glycoprotein enhanced the chemosensitivity by up to
4.5 fold (C-4 treated JJ012: 11.46 ± 3.37%, p < 0.05) at 0.1
μM and 4 fold (C-4 treated SW1353: 17.36 ± 1.58%, p <
0.05) at 1 μM in comparison to each control group on
flowcytometric examination (Figures 3A and 3B). In addi-
tion, the combination of inhibitors for antiapoptotic pro-
teins and P-glycoprotein enhanced the chemosensitivity
by up to 5.5 fold (Bcl-2 inhibitor+C-4 treated JJ012: 13.93
± 2.76%, p < 0.01) at 0.1 μM, 5.5 fold (embelin+C-4
treated SW1353:23.51 ± 3.50%, p < 0.01) at 1 μM. The
increase in the chemosensitizing effect by combinatorial
use of antiapoptotic protein and P-glycoprotein inhibitors
was maximal when P-glycoprotein (C-4) and XIAP (embe-
lin) were inhibited simultaneously in doxorubicin treat-
ment (Figure 3B).
To examine the mechanism of doxorubicin and inhibitor
induced cell death in chondrosarcoma cells, we obtained
cytosolic and mitochondrial fractions and measured cyto-
chrome c expression after treatment of doxorubicin in the
presence or absence of inhibitors. Doxorubicin treatment
with inhibitors of antiapoptotic protein or P-glycoprotein
induced cytochrome c release from mitochondria to
cytosol (Figure 3C). However, doxorubicin treatment
alone did not trigger mitochondrial cytochrome c release
significantly. These data suggest inhibition of antiapopto-
sis proteins and P-glycoproteins enhance doxorubicin
sensitivity by the cytochrome c release mechanism.
There is a possibility that antiapoptotic protein inhibitors
treatment may change the function or the expression of P-
Cell surface expression of P-glycoprotein and doxorubicin  uptake and efflux in chondrosarcoma cells Figure 2
Cell surface expression of P-glycoprotein and doxo-
rubicin uptake and efflux in chondrosarcoma cells. (A) 
Cell surface P-glycoprotein expression was detected by flow 
cytometric analysis. Cell surface P-glycoprotein staining was 
positive in two chondrosarcoma cells. (IgG: isotype IgG con-
trol, PG: P-glycoprotein antibody) (B) Doxorubicin uptake 
was measured in two chondrosarcoma cells. Doxorubicin 
uptake increased as doxorubicin concentration was 
increased in the two chondrosarcoma cell lines. (C) Func-
tional assay of P-glycoprotein was performed after doxoru-
bicin washout. Doxorubicin levels were measured at 1, 6 and 
24 hours after washout after 1 hour treatment. Doxorubicin 
levels decreased in a time dependant manner.Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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glycoprotein instead of the direct effect on antiapoptotic
proteins in P-glycoprotein expressing chondrosarcoma
cells. To investigate the possibility, we performed doxoru-
bicin efflux assay and measured P-glycoprotein  mRNA
expression by RT-PCR after treatment of antiapoptotic
protein inhibitors. Antiapoptotic inhibitors treatment
(Bcl-2 inhibitor, embelin) changed P-glycoprotein func-
tion, but it was not significant (Figure 4A). Only C-4 treat-
ment (P-glycoprotein inhibitor) inhibited doxorubicin
efflux significantly compared with DMSO control (Figure
4A). None of the inhibitors treatment changed mRNA
expression of P-glycoprotein (Figure 4B). These data suggest
antiapoptotic proteins and P-glycoprotein may be inde-
pendent chemoresistant mechanisms in chondrosarcoma
cells.
Antiapoptotic and P-glycoprotein gene silencing 
enhances doxorubicin sensitivity
We also tested our hypothesis that both antiapoptotic
proteins and P-glycoprotein play an important role in the
chemoresistance of chonodrosarcoma cells using siRNA.
First, we examined intracellular uptake of siRNA which
has a fluorescent tag. Chondrosarcoma cells showed fluo-
rescence in the cytoplasm 24 hours after transfection with
fluorescence protein tagged siRNA (Figure 5A). We exam-
ined the P-glycoprotein drug-exporting function after P-
glycoprotein  gene silencing. P-glycoprotein knockdown
decreased doxorubicin efflux significantly (Figure 5B).
Next, immunoblotting was used to confirm siRNA's target
gene knockdown effect (Figure 5C). Target protein expres-
sion of each siRNA was significantly decreased in compar-
ison to the control groups. To determine whether
targeting antiapoptotic genes may affect the expression of
P-glycoprotein or vice versa, protein expression was meas-
ured by quantifying the density of immunoblot bands
adjusted to GAPDH using ImageJ software and mRNA
expression of P-glycoprotein was measured by RT-PCR after
siRNA treatment. Targeting any of the antiapoptic genes
did not change mRNA and protein expression of P-glyco-
protein  gene significantly compared with non-silencing
control (Figure 5D and Figure 6). Targeting the P-glycopro-
tein gene did not change any of the antiapoptotic proteins
expression, either (Figure 6). These data support our
inhibitors experiment finding (Figure 4A, 4B), which sug-
gests antiapoptotic proteins and P-glycoprotein are inde-
pendent doxorubicin resistant mechanisms in
chondrosarcoma cells.
We calculated the following target gene knockdown effi-
ciency with 1 μg/ml of siRNA (SW1353; Bcl-2: 39 ± 5.1%,
Bcl-xL: 72 ± 10.3%, XIAP: 66 ± 12.2%, P-glycoprotein: 47 ±
6.8%. JJ012; Bcl-2: 57 ± 10.2%, Bcl-xL: 75 ± 11.7%, XIAP:
70 ± 9.6%, P-glycoprotein: 62 ± 9.9%). Apoptosis rates were
measured with annexin V after chondrosarcoma cells were
treated with 1 μg/ml of siRNA and two different concen-
Apoptosis after inhibitor and doxorubicin treatment Figure 3
Apoptosis after inhibitor and doxorubicin treatment. 
(A) Microscopic pictures after inhibitor and doxorubicin 
treatment are shown. Chondrosarcoma cells treated with 10 
μM of Bcl-2 inhibitor, 10 μM of C-4 (P-glycoprotein inhibi-
tor) or 10 μM of embelin (XIAP inhibitor) showed more 
apoptotic cells than control groups after doxorubicin treat-
ment. (Bcl-2 inh: Bcl-2 inhibitor, original magnification ×100). 
(B) The effect of inhibitors on chemosensitivity in chondrosa-
rcoma cells is shown. Inhibitor treatment enhanced chemo-
sensitivity. Inhibitor treated chondrosarcoma cells 
demonstrated increased apoptosis after doxorubicin treat-
ment in comparison to the control groups (up to 4.5 fold 
increase). Combination treatment of inhibitors (Bcl-2 inh + 
C-4 and embelin + C-4) showed significant increase in apop-
tosis. (Bcl-2 inh: Bcl-2 inhibitor, *: p < 0.05 and **: p < 0.01) 
(C) Immunoblotting demonstrates cytochrome c release 
from mitochondria to cytosol after treatment with doxoru-
bicin and inhibitors. Cytochrome oxidase IV (COX IV) 
serves as a marker for mitochondria.
Function and mRNA expression of P-glycoprotein after  inhibitor treatment Figure 4
Function and mRNA expression of P-glycoprotein 
after inhibitor treatment. (A) Doxorubicin efflux was 
measured after inhibitor treatment. Only C-4 (P-glycopro-
tein inhibitor) treatment inhibited doxorubicin efflux signifi-
cantly. (Bcl-2 inh: Bcl-2 inhibitor) (B) mRNA expression of P-
glycoprotein was measured by RT-PCR. All inhibitors did not 
change mRNA expression of P-glycoprotein. mRNA expres-
sion of P-glycoprotein of each inhibitor treatment was divided 
by mRNA expression of DMSO control. (Bcl-2 inh: Bcl-2 
inhibitor).Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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trations of doxorubicin (0.1 μM and 1 μM). While the
untreated chondrosarcoma cells exhibited chemoresist-
ance,  Bcl-2,  Bcl-xL  and  XIAP  gene silencing enhanced
chemosensitivity by up to 2.7 fold (XIAP siRNA treated
JJ012: 9.97 ± 1.47%, p < 0.05) at 0.1 μM and 3.3 fold (Bcl-
xL siRNA treated JJ012: 16.90 ± 3.84%, p < 0.01) at 1 μM
in comparison to each nonsilencing control group (JJ012:
3.63 ± 1.27% at 0.1 μM, 5.12 ± 1.49% at 1 μM) on flow
cytometric examination (Figure 7A and 7B). P-glycoprotein
gene silencing also enhanced chemosensitivity signifi-
cantly at 0.1 μM (SW1353: 9.65 ± 1.98%, JJ012: 9.83 ±
1.72%, p < 0.05) and 1 μM (SW1353: 14.12 ± 3.03%,
JJ012: 17.99 ± 3.77%, p < 0.05) in comparison to each
nonsilencing control group. Additionally, dual gene
silencing of both the antiapoptotic gene and P-glycoprotein
gene enhanced chemosensitivity by up to 4.1 fold
(XIAP+PG siRNA treated JJ012: 15.04 ± 1.60%, p < 0.01)
at 0.1 μM, and 4.2 fold (XIAP+PG siRNA treated JJ012:
21.96 ± 2.79%, p < 0.01) at 1 μM. Interestingly, antiapop-
totic or P-glycoprotein gene silencing without doxorubicin
treatment caused a very modest induction of apoptosis
(Figure 7B). Overall, the use of target protein specific
siRNA and doxorubicin increased chemosensitivity by 4
to 14 folds in comparison to untreated cells.
Antiapoptotic or P-glycoprotein gene silencing with 
chemotherapy decreases cell survival and proliferation
Tumor recurrence is a prognostic factor which negatively
affects clinical outcome following radiation or chemo-
therapy. We hypothesize that anti-apoptotic or P-glyco-
protein gene silencing in combination with
chemotherapy decreases both survival and proliferation
of chondrosarcoma cells. Clonogenic cell survival assays
were conducted and showed that chondrosarcoma cells
still have the ability to proliferate and form multiple col-
onies after doxorubicin treatment (Figure 8). When antia-
poptotic or P-glycoprotein genes were silenced in cells that
underwent chemotherapy, the number of colonies
decreased significantly (p < 0.05). Antiapoptotic gene
silencing decreased colony formation by up to three fold
(p < 0.05) at 0.1 μM, in comparison to the control group.
At the highest dose of doxorubicin (1 μM), there was no
significant colony formation in any siRNA treated group.
Discussion
There is no effective treatment for metastatic or unresecta-
ble chondrosarcomas due to the chemo- and radioresist-
ant properties of such cancers. In this regard, a better
understanding of the molecular mechanisms responsible
for chemo- and radioresistance is necessary to develop
novel therapeutic strategies. Failure of chemotherapy
results from both patient and tumor variances. The host
siRNA gene silencing Figure 5
siRNA gene silencing. (A) A fluorescent microscopy pic-
ture demonstrates intracellular localization of siRNA tagged 
with green fluorescent protein (GFP). Most GFP tagged 
siRNA was seen in the cytoplasm while the nuclei (N) lack 
green fluorescence. (B) Doxorubicin level was measured 
after P-glycoprotein siRNA treatment. P-glycoprotein siRNA 
treatment increased doxorubicin level at 0.1 and 1 μM in 
comparison to Non-Silencing control siRNA. (NS: Non-
Silencing siRNA, PG: P-glycoprotein siRNA) (C) Immunoblot-
ting demonstrates decreased expression of Bcl-2, Bcl-xL, 
XIAP and P-glycoprotein by siRNA. (-: carrier only, NS: Non-
silencing siRNA, PG: P-glycoprotein) (D) Targeting antiapop-
totic gene (Bcl-2, Bcl-xL and XIAP) did not change mRNA 
expression of P-glycoprotein. Only P-glycoprotein siRNA treat-
ment decreased mRNA expression of P-glycoprotein. mRNA 
expression of P-glycoprotein of each siRNA treatment was 
divided by mRNA expression of nonsilencing control. (NS: 
Nonsilencing siRNA, PG: P-glycoprotein).
Quantification of protein expression after siRNA gene silenc- ing Figure 6
Quantification of protein expression after siRNA 
gene silencing. Protein expression was quantified by ImageJ 
software after siRNA gene silencing. Only targeted gene 
expression changed significantly compared with gene expres-
sion of non-silencing control. Non-target gene expression did 
not change significantly. (NS: Nonsilencing siRNA, PG: P-glyc-
oprotein).Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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factors include poor absorption, rapid metabolism and
insufficient drug delivery to the tumor site, while the
tumor factors include the loss of cell surface receptors or
drug transport proteins, specific metabolism of chemo-
therapy drugs, mutation of the specific target of drugs, and
the increase in drug efflux [25]. Drug efflux has been stud-
ied extensively, since it has the most relevance to multid-
rug resistance. Consequently, it is believed that the major
mechanism of multidrug resistance in tumor cells is P-
glycoprotein expression [26]. Several in vitro studies have
already reported that most chondrosarcoma cells express
P-glycoprotein to confer MDR [5,7]. Our experiments
have confirmed this as previously reported by other
groups (Figure 1B). Doxorubicin resistant normal carti-
lage and chondrosarcoma cells express high levels of
antiapoptotic proteins as well as P-glycoprotein, suggest-
ing that both P-glycoprotein and antiapoptotic proteins
may contribute to doxorubicin resistance.
P-glycoprotein is located on the plasma membrane which
removes cytotoxic drugs from the cell. It is believed to be
the main mechanism of chemoresistance in P-glycopro-
tein expressing tumors regardless of antiapoptotic gene
expression since cytotoxic drugs were thought to be
removed before antiapoptotic proteins would work. How-
ever, our data reveals that doxorubicin uptake increases
with higher doses in P-glycoprotein expressing chondro-
sarcoma cells (Figure 2B) and antiapoptotic protein inhi-
bition and gene silencing enhanced doxorubicin
sensitivity independent of P-glycoprotein (Figures 3B and
7B). Additionally, significant amounts of doxorubicin still
remained in chondrosarcoma cells 24 hours after doxoru-
bicin washout (Figure 2C).
Our results suggest that antiapoptotic proteins play a role
in the chemoresistance of chondrosarcoma cells by
enhancing cell survival in addition to P-glycoprotein.
These antiapoptotic proteins and P-glycoprotein are two
independent chemoresistance mechanisms in chondrosa-
rcoma cells since targeting antiapoptotic proteins did not
have any effect on the activity, mRNA expression level and
protein expression level of P-glycoprotein (Figure 4A, B,
5D and 6) and targeting P-glycoprotein did not change
the expression level of antiapoptotic proteins, either (Fig-
ure 6). The two independent mechanisms are closely
related in terms of a cell death pathway by blocking cyto-
chrome c release for doxorubicin resistance in chondrosa-
rcoma cells (Figure 3C and 9). We also found targeting
both P-glycoprotein and antiapoptotic protein with doxo-
rubicin treatment showed additive effect rather than syn-
ergistic effect (Figure 3B and 7B). This may be due to the
fact that apoptosis which results from targeting antiapop-
totic proteins, induces the cleavage of P-glycoprotein [27]
which may weaken the effect of targeting P-glycoprotein.
Among the antiapoptotic genes screened, the knockdown
of Bcl-xL and XIAP enhanced doxorubicin sensitivity as
effectively as P-glycoprotein and the combined knockdown
of Bcl-xL with P-glycoprotein and XIAP with P-glycoprotein
were significantly effective in our dual gene silencing
group (Figure 7A and 7B). This may be explained by the
fact that Bcl-xL and XIAP overexpression in P-glycoprotein
expressing tumor cells has been associated with a much
stronger resistance to treatment and a worse prognosis
[12,28]. Moreover, apoptosis itself induces the cleavage of
P-glycoprotein, which may enhance apoptotic sensitivity
[27].
Yet, the knockdown of Bcl-2 did not induce significant
apoptosis in SW1353 chondrosarcoma cells (Figure 7B)
while Bcl-2 inhibitor treatment enhanced doxorubicin
sensitivity in SW1353 cells (Figure 3B). This may be due
to the low knockdown efficiency of Bcl-2 (SW1353; Bcl-2:
39 ± 5.1%, Bcl-xL: 72 ± 10.3%, XIAP: 66 ± 12.2%, P-glyco-
protein: 47 ± 6.8%. JJ012; Bcl-2: 57 ± 10.2%, Bcl-xL: 75 ±
11.7%, XIAP: 70 ± 9.6%, P-glycoprotein: 62 ± 9.9%). In
addition, Bcl-2 inhibitor inhibits Bcl-xL as well as Bcl-2
Apoptosis after siRNA and doxorubicin treatment Figure 7
Apoptosis after siRNA and doxorubicin treatment. 
(A) Microscopic pictures after siRNA and doxorubicin treat-
ment are shown. Chondrosarcoma cells treated with siRNAs 
showed more apoptotic cells than control groups after dox-
orubicin treatment (NS: nonsilencing siRNA, PG: P-glycopro-
tein, original magnification ×100). (B) The effect of gene 
silencing on chemosensitivity in chondrosarcoma cells is 
shown. siRNA treatment enhanced chemosensitivity. siRNA 
treated chondrosarcoma cells demonstrated increased apop-
tosis after doxorubicin treatment in comparison to the con-
trol groups (up to 3.3 fold increase). Dual gene silencing (Bcl-
xL+PG and XIAP +PG siRNA) also increased apoptosis signifi-
cantly. (NS: nonsilencing siRNA, PG: P-glycoprotein, *: p < 
0.05, +: p < 0.01, Nonsilencing siRNA treated group was 
used as a control for p-value.)Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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since Bcl-2 inhibitor competes with Bak BH3 peptide for
binding to Bcl-2 and Bcl-xL [24]. Consequently, we could
not establish its role in chemoresistance. There are several
factors which can explain this discrepancy in the knock-
down efficiency of each target protein. siRNA efficiency
can be determined by the cell type, passage number, con-
fluency of cells, turnover rate of proteins, and the stability
of proteins [29]. Each protein has different turnover rates
and stabilities which is why our siRNA knockdown effi-
ciency is quite different for each target protein.
Although chondrosarcoma cells are resistant to doxoru-
bicin, clonogenic survival data showed that the colony
numbers of the untreated groups were decreased signifi-
cantly at 0.1 and 1 μM of doxorubicin. This may be the
result of a number of factors including trypsinization and
the small number of cells seeded, in addition to doxoru-
bicin's effect.
We used Grade II chondrosarcoma cells which are well
characterized and have been widely used by other investi-
gators [19-21]. Grade III chondrosarcoma cells could be a
more attractive experimental model but grade III chond-
rosarcoma cells often lose cartilage phenotypes with more
heterogeneous cellularity. Hence, grade II chondrosarco-
mas were the best choice for our purposes since they have
a high resistance to both chemo- and radiotherapy, meta-
static potential and a high recurrence rate but still main-
tain the cartilaginous phenotype. Although our study was
limited to Grade II chondrosarcomas, the proposed ther-
apeutic concept may be relevant to other high grade sarco-
mas including Grade III chondrosarcomas which
overexpress P-glycoprotein and antiapoptotic proteins
[3,6].
In summary, our data suggest that antiapoptotic proteins
as well as P-glycoprotein confer chemoresistance to P-
glycoprotein expressing chondrosarcoma cells (Figure 9).
As a result, antiapoptotic gene and P-glycoprotein silencing
via siRNA possibly could be used as a molecular adjuvant
therapy for metastatic or surgically unresectable chondro-
sarcomas. However, additional in vivo studies will be nec-
essary before applying the proposed therapeutic concept
in clinical trials.
Methods
Chondrosarcoma and Normal Chondrocyte Cell Cultures
Two well-establised Grade II chondrosarcoma and two
normal chondrocyte cell lines were used. The chondrosa-
rcoma cell line, JJ012, was obtained from Dr. Joel A. Block
(Rush Medical College, Chicago, Illinois, USA), and the
other chondrosarcoma cell line, SW1353, was purchased
from American Type and Culture Collection (Manassas,
Maryland, USA). Two normal articular chondrocyte tissue
samples were harvested from patients after obtaining IRB
approval. Cartilage specimens were minced with scissors
in DMEM (Invitrogen, Carlsbad, California, USA), pro-
ducing a cell suspension of small tissue fragments. The
suspension was pelleted by centrifugation and the tissue
fragments were digested enzymatically in phosphate buff-
ered saline (PBS) containing 1 mg/ml collagenase, 0.15
mg/ml DNAse, and 0.15 mg/ml hyaluronidase (Sigma, St.
Louis, Missouri, USA) for 1 hour at 37°C. The cells were
grown at 37°C in a humidified atmosphere containing
5% CO2 and 95% air. The culture medium consisted of
40% Dulbecco's modification of Eagle's medium, 40%
MEM-α, F-12 (Invitrogen, Carlsbad, CA), 10% fetal
bovine serum (Gembio, Woodland, California, USA), 100
ng/ml human insulin (Lilly, Indianapolis, Indiana, USA),
25  μg/ml ascorbic acid, and 100 nM hydrocortisone
(Sigma, St. Louis, Missouri, USA). The culture medium
was changed every three to four days.
RNA Interference Targeting Anti-Apoptotic Genes and P-
glycoprotein
The siRNAs targeting Bcl-2, Bcl-xL, XIAP and P-glycoprotein
were obtained from Ambion (Austin, Texas, USA). Chon-
drosarcoma cells that were not treated with siRNAs or
those treated with non-silencing siRNAs were used as neg-
ative controls. The delivery of siRNAs was verified by
using FITC tagged negative control siRNAs (Qiagen,
Valencia, California, USA) and X-tremeGENE siRNA
transfection reagent (Roche, Branchburg, New Jersey,
USA) as a carrier. Manufacturer's protocol was followed
for siRNA transfection. We have reported that the optimal
siRNA concentration is 1 μg/ml and gene silencing effect
of siRNA is maximal on day 2 after siRNA transfection in
SW1353 and JJ012 chondrosarcoma cells [4]. Therefore,
transfection was carried out using 1 μg/ml of siRNA for
single siRNA treatment groups and 0.5 μg/ml of each
siRNA for dual treatment groups to make the total
amount of siRNA administered 1 μg/ml. Doxorubicin was
treated 48 hours after siRNA treatment.
Clonogenic survival after siRNA and doxorubicin treatment Figure 8
Clonogenic survival after siRNA and doxorubicin 
treatment. Clonogenic survival after chemotherapy and 
siRNA is shown. siRNA treatment with chemotherapy 
decreases colony formation by two times. Combinatorial 
siRNA treatments (Bcl-xl + PG or XIAP + PG siRNA) inhib-
ited colony formation effectively after doxorubicin treat-
ment. (PG: P-glycoprotein, *: p < 0.05).Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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Flow Cytometry after Annexin V Staining
The culture conditions were identical for both control and
experimental groups. Chondrosarcoma cells and normal
chondrocytes were grown in six-well plates and treated
with 0, 0.1, and 1 μM of doxorubicin for 24 hours once a
confluency of 80% had been reached. Human embryonic
kidney cells (HEK cells) were used as a control to verify the
cytotoxic effects of doxorubicin where the dose was cho-
sen based on peak plasma level (1–2 μg/ml or 1.7–3.4
μM) in patients receiving a standard doxorubicin treat-
ment [30]. Another set of chondrosarcoma cells were pre-
treated with inhibitors including Bcl-2 inhibitor (2,9-
Dimethoxy-11,12-dihydrodibenzo-diazocine 5,6-dioxide
and 5,5'-Dimethoxy-2,2'-dinitrosobenzyl, Calbiochem,
San Diego, California, USA), C-4 (Calbiochem, San
Diego, CA) and embelin (Calbiochem, San Diego, CA) 24
hours prior to doxorubicin treatment or with siRNAs that
targeted Bcl-2, Bcl-xL, XIAP  and P-glycoprotein  48 hours
before doxorubicin treatment. Flow cytometric analysis
was used to identify cells undergoing apoptosis. After
trypsinizing the cells, they were stained with APC conju-
gated Annexin V (BD Pharmingen, San Diego, CA).
Stained cells were then counted with a flow cytometer
(FACS Calibur; Becton Dickinson Science, San Jose, CA).
Doxorubicin Efflux Assay
Doxorubicin efflux assays were carried out as previously
described [7]. In brief, cells were exposed with doxoru-
bicin contained medium for 1 hour and washed with PBS
two times. Then cells were incubated in doxorubicin-free
medium for 1, 6 and 24 hours and harvested for measure-
ment of autofluorescent doxorubicin (excitation wave-
length: 480 nm, emission wavelength: 580 nm) with a
flow cytometer.
Clonogenic Survival Assay
The clonogenic survival assay was used to determine the
capacity for cell survival and proliferation after radiation
or chemotherapy [31]. After treatment with siRNA and
doxorubicin, 1000 cells from each group were seeded
onto 60 mm cell culture plates containing the culture
medium. Fifteen days later, the cells were stained with
crystal violet (Sigma, St. Louis, Missouri, USA). Colonies
larger than 50 cells were counted at low magnification.
Immunoblotting
Immunoblotting assays were conducted in order to deter-
mine the expression of P-glycoprotein and anti-apoptotic
proteins by chondrosarcoma cells and the effect of gene
silencing. The cells were lysed using buffer IP (10 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.25%
Nonidet P-40, and 2 mM EDTA) supplemented with a
protease inhibitor cocktail (Roche, Branchburg, New Jer-
sey, USA). Equivalent protein extracts (10 μg) from each
sample were electrophoresed in 4–20% Tris-Glycine gels
(Invitrogen, Carlsbad, CA). For mitochondrial and
cytosolic fraction, cells were washed with ice-cold PBS and
lysis buffer A (20 mM HEPES pH7.5, 0.1% BSA, 0.1 μM
PMSF, 1 mM EDTA, 1 mM DTT, 20 μg/ml leupeptin, 10
μg/ml aprotinin, 10 μg/ml pepstatin A) containing 250
mM of sucrose was added. After 10 min incubation on ice,
cells were homogenized with a dounce homogenizer and
centrifuged at 700 × g for 5 min at 4°C. Supernatants were
centrifuged at 10,000 × g for 30 min at 4°C. The resulting
supernatants were used as the cytosolic fraction and the
mitochondria pellets were resuspended with lysis buffer
A. Equivalent protein extracts (60 μg for mitochondrial
fraction and 120 μg for cytosolic fraction) from each sam-
ple were electrophoresed in 4–20% Tris-Glycine gels (Inv-
itrogen). The total amount of protein was quantified
using the BCA assay. The protein was transferred to an
Immun-Blot PVDF membrane (Bio-Rad, Hercules, Cali-
fornia, USA) which was then incubated with Bcl-2, Bcl-xL,
XIAP (Cell Signaling, Beverly, MA), α-actin (Sigma, St.
Louis, Missouri, USA), P-glycoprotein (Calbiochem, San
Diego, California, USA) and GAPDH antibodies (Chemi-
con, Temecula, California, USA). The signal strength of
each immunoblot band was normalized to GAPDH and
quantified using the ImageJ software.
Quantitative Real Time RT-PCR
Total RNA was isolated from cells using an RNeasy Mini
Kit (Qiagen, Valencia, California, USA) according to the
Doxorubicin resistance mechanisms in chondrosarcoma cells Figure 9
Doxorubicin resistance mechanisms in chondrosar-
coma cells. A schematic diagram demonstrates a molecular 
pathway of apoptosis that is triggered by doxorubicin. Doxo-
rubicin damages DNA. This DNA damage induces cyto-
chorome C release in mitochondria which activates caspases, 
the effectors of apoptosis. P-glycoprotein inhibits doxoru-
bicin effect by drug efflux. Bcl-2 and Bcl-xL block cytochrome 
c release. XIAP inhibits caspase activation.Molecular Cancer 2009, 8:28 http://www.molecular-cancer.com/content/8/1/28
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manufacturer's guidelines. Single stranded cDNA was syn-
thesized from total RNA with the SuperScript III system
(Invitrogen). Real time RT-PCR for each target was per-
formed with LightCycler FastStart DNA MasterPLUS SYBR
Green I (Roche Diagnostics Corporation, Indianapolis,
Indiana, USA) using the Smart Cycler® System (Cepheid,
Sunnyvale, California, USA). Primers sets used were: for
GAPDH, (5'-AGAACATCATCCCTGCATCC-3') and (5'-
AGTTGCTGTTGAAGTCGC-3'); for P-glycoprotein, (5'-
AACAACGCATTGCCATAGCTCGTG-3') and (5'-AGTCT-
GCATTCTGGATGGTGGACA-3'). The thermal cycling
condition consisted of pre-heating (10 minutes at 94°C)
and 40 cycles of denaturation (10 seconds at 94°C),
annealing (20 seconds at 60°C) and elongation (20 sec-
onds at 72°C). Each mRNA level was normalized with the
internal control GAPDH mRNA level.
Statistical Analysis
Experiments were performed three times and in triplicate
at each time. Statistical analysis was performed using the
Statistical Package for the Social Sciences (SPSS) software
(version 13, Chicago, Illinois, USA). Differences between
each control and experimental groups were analyzed by
using one-way analysis of variance between groups
(ANOVA/Scheffe), and p < 0.05 was considered statisti-
cally significant.
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